BTB Pharma takes a leap for healing autoimmune diseases

A relatively new actor in the biopharmaceutical industry, BTB Pharma is a developer of a revolutionary biomedical platform for the treatment of autoimmune disease.

With an antigen-specific approach, the platform technology targets the cause of disease, not just the symptoms. This technology incorporates a two-component concept, creating a synergistic effect between the first component, which binds unique cells in the immune system, with the second component, which is disease-specific.

This configuration allows the treatment to combat a number of different autoimmune diseases. Currently, BTB Pharma’s aspirations lie in the treatment of Multiple Sclerosis and Type 1 Diabetes. Specific treatments are currently in a Proof of Concept format, and are being tested in relevant animal models.

Autoimmune diseases

More than 80 autoimmune diseases have been identified so far. They are chronic diseases in which the body’s immune system attacks its own organs and tissues. Multiple Sclerosis (MS), Type I Diabetes (TID), Rheumatoid Arthritis (RA) and allergy belong to the most common diseases. Collectively, autoimmune diseases are thought to affect approximately 1 in 5 people in the Western world. They also represent a significant physical, emotional, social, and financial burden to the country. There are drugs on the market that can reduce the symptoms, but there are no drugs so far that can cure autoimmune diseases.

BTB Pharma Receives Grant From Vinnova

BTB Pharma receives grant from Vinnova

BTB Pharma AB has been awarded a grant "Innovativa startups 2017" by Vinnova to develop a treatment for the chronic inflammatory disease, multiple sclerosis (MS). We have previously identified components that prevented the development of MS, in an animal model. The problem was that those components were not compatible for…

read more